The Second Genome Precision Therapeutics program includes Immuno-oncology, aimed at improving response to immune checkpoint inhibitors (ICIs) by augmenting T cell activation and inducing anti-tumor immunity. The program also addresses Gastrointestinal Disorders, with a primary focus on improving barrier function in GI disease.